Focused On-demand Library for Regulator of G-protein signaling 19

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P49795

UPID:

RGS19_HUMAN

Alternative names:

G-alpha-interacting protein

Alternative UPACC:

P49795; A8K216; E1P5G9; Q53XN0; Q8TD60

Background:

The Regulator of G-protein signaling 19 (RGS19) is a pivotal protein that modulates signal transduction pathways. It achieves this by enhancing the GTPase activity of G protein alpha subunits, leading them to their inactive GDP-bound form. RGS19 exhibits a preference for G-alpha subfamily 1 members, showcasing a binding affinity hierarchy. This protein, also known as G-alpha-interacting protein, plays a critical role in the regulation of cellular responses to external signals.

Therapeutic significance:

Understanding the role of Regulator of G-protein signaling 19 could open doors to potential therapeutic strategies. Its ability to modulate signal transduction pathways positions it as a key target for drug discovery efforts aimed at regulating cellular processes implicated in various conditions.